Dr. Briggs Morrison is Chief Executive Officer of Crossbow Therapeutics and was President, Head of R+D at Syndax Pharmaceuticals, and is an Executive Partner at MPM Capital. Prior to joining Syndax Pharmaceuticals, he joined Merck & Co., Inc. and was appointed Head of Clinical Development at Pfizer. Additionally, Dr. Morrison became Head of Global Medicines Development and Chief Medical Officer at AstraZeneca. Dr. Morrison has overseen the development of numerous biopharmaceutical products in multiple therapeutic areas, from first-in-human trials through to global regulatory approvals.
He is currently a board member of Carisma Therapeutics, Syndax Pharamceuticals, Werewolf and Repare Therapeutics and is an advisor to several other private biotechnology companies. Dr. Morrison received his B.S. in Biology from Georgetown University, his M.D. from the University of Connecticut Medical School, completed residency training in Internal Medicine at the Massachusetts General Hospital, and completed a fellowship in Medical Oncology at Dana-Farber Cancer Institute. He did postdocs with Philip Leder at Harvard Medical School, and Lee Nadler at the Dana-Farber Cancer Institute.